Context: Reliable localization of insulinoma is critical for successful treatment.
I
nsulinoma is the most common functional pancreatic neuroendocrine tumor, with an incidence of 0.1 to 0.3 cases per 100,000 persons per year (1) . In over 90% of cases, they are solitary and benign. Patients present with symptoms of hypoglycemia, with blood glucose in the range of 40 to 50 mg/dL, and show resolution of symptoms with glucose administration, otherwise known as the Whipple triad (2). The diagnosis is confirmed by the demonstration of inappropriately elevated insulin and proinsulin levels associated with serum glucose values of ,50 mg/dL during the 48-hour fast period (3, 4) . Insulinoma may be associated with a hereditary syndrome in nearly 10% of patients, the most common being multiple endocrine neoplasia type 1 (MEN1) (5) .
Insulinomas are evenly distributed throughout the pancreas and are usually less than 2 cm in size in approximately 90% of cases (1) . This makes them challenging to localize by traditional imaging techniques such as transabdominal ultrasound, contrast-enhanced computed tomography (CT), and magnetic resonance imaging (MRI). Preoperative invasive localizing studies for insulinoma include endoscopic ultrasound with sensitivity of 75% (6) , or selective arterial secretagogue injection (SASI) of the major pancreatic arteries with hepatic venous sampling for insulin to regionalize the insulinoma within the pancreas, which has a sensitivity of up to 88% (7) . Exploratory laparotomy with intraoperative ultrasound (IO ultrasound) and bimanual palpation of the pancreas is the most sensitive way to detect insulinoma(s) (7, 8) . In cases when intraoperative evaluation fails to localize an insulinoma, blind pancreatic resection is not recommended (9) . Detection of insulinoma using 68 Gallium (Ga)-DOTA peptide has been previously reported. Different radioligands targeting somatostatin receptors, including 68 Ga-DOTA-(Tyr3)-octreotate (DOTATATE), 68 Ga-DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC), and 68 Ga-DOTA-1-NaI3-octreotide (DOTANOC), have been evaluated for detection of neuroendocrine tumors with promising results (10, 11) .
68
Ga-DOTATATE/DOTATOC positron emission tomography (PET)/computed tomography (CT) has been described in the detection of insulinomas (12) . The aim of this study was to evaluate the accuracy of 68 Ga-DOTATATE PET/CT as compared with other anatomic imaging modalities, SASI, and IO ultrasound and palpation for localizing insulinoma in patients who were biochemically cured of their insulinomas.
Materials and Methods
Patients were evaluated for insulinoma at the National Institutes of Health (NIH) Clinical Center and underwent a resection of their insulinoma. We included patients who had insulinoma confirmed by histopathology in our cohort. Patients with insulinoma were enrolled in a clinical protocol evaluating the accuracy of 68 Ga-DOTATATE PET/CT (NCT01967537) after written informed consent was obtained. This prospective study was performed under an investigational new drug protocol approved by the US Food and Drug Administration. The study was reviewed and approved by the National Cancer Institute review board and the NIH Radiation Safety Committee.
We performed a retrospective analysis of 31 patients who underwent surgery for insulinoma at the NIH Clinical Center between 4 November 2009 and 24 August 2016 and had insulinoma confirmed by histology and were biochemically cured. Patients' laboratory evaluations included measurements of fasting glucose, insulin, proinsulin, and C-peptide, as well as the duration of the fast until hypoglycemia was documented. The imaging results for CT, MRI, and ultrasound and 68 Ga-DOTATATE, SASI, and intraoperative findings were correlated to the histopathology finding.
68 Ga-DOTATATE scans were performed in 10 patients as previously described (13, 14) . Five mCi of 68 Ga-DOTATATE was administered through a peripheral vein. After approximately 60 minutes, the patient was placed in a supine position in a PET/CT scanner (Siemens Medical Solutions USA, Inc., Malvern, PA), and images from the upper thighs to skull (including pituitary gland) were obtained. A low-dose, noncontrast CT was used for attenuation correction and anatomic localization. Maximum standardized uptake values were measured based on patient total body weight.
Data analyses
We analyzed the 68 Ga-DOTATATE PET/CT uptake status by patient demographic, clinical characteristics, familial vs sporadic insulinoma, and laboratory data. Spearman's correlation coefficient, Student t test, and x 2 tests were used to test for associations between clinical, pathology, and operative variables in patients who did and did not have 68 Ga-DOTATATE PET/CT imaging to evaluate 68 Ga-DOTATATE PET/CT imaging's impact on patient care. P , 0.05 was considered statistically significant. IBM SPSS Statistics Data Editor (New York, NY) and Microsoft Excel (Redmond, WA) were used for statistical analyses.
Results

Clinical characteristics
All patients (N = 31) had a supervised fast with a median duration of 12.5 hours (range: 3 to 41 hours) and the median fasting end glucose was 38 mg/dL (range: 27 to 49). Twentyseven patients had sporadic insulinoma, and 4 patients had MEN1-associated insulinoma. The demographic and clinical characteristics of the study cohort are summarized in Table 1 . Thirteen patients (42%) underwent an open resection of the insulinoma, 10 patients (32%) had a handassisted laparoscopic resection, and 8 patients (26%) had a laparoscopic resection. All patients, at the last follow-up, were biochemically cured of their insulinoma. A comparison of patients who had 68 Ga-DOTATATE imaging to those who did not revealed no significant difference in age, body mass index, glucose, C-peptide, insulin, and proinsulin before and after supervised fasting between those patients (Table 1 ). There was also no significant difference in the type of operation and duration of the operation and perioperative outcomes based on having a positive 68 Ga-DOTATATE PET/CT scan as compared with patients who did not have the imaging study ( Fig. 1 and Table 1 ).
Accuracy of
68 Ga-DOTATATE PET/CT Ten patients underwent a 68 Ga-DOTATATE scan, and 9 out of 10 (90%) had an insulinoma successfully localized. In 9 patients, the tumor was regionalized using SASI, and the median size of insulinoma was 1.5 cm (range: 0.7 to 2.5 cm). The gold standard for defining a positive localization result was histology. In all 10 patients, the tumors stained positive for insulin and were well differentiated. Eight out of 9 tumors had a Ki-67 of less than 2% (World Health Organization grade I); 1 had a Ki-67 of 3% to 5% (World Health Organization grade II; 68 Ga-DOTATATE positive). In 4 patients, the tumor was localized to the distal pancreas; in 3 patients, to the head of the pancreas; and in 3 patients, to the body of the pancreas. Other imaging modalities performed in the 10 patients included CT, MRI, and ultrasound. Transabdominal ultrasound did not identify an insulinoma in any of the 10 patients. A CT scan accurately localized the insulinoma in 6 out of the 10 patients, and an MRI localized the insulinoma in 8 of the 10 patients. The patient with negative 68 Ga-DOTATATE underwent an enucleation of an uncinate process insulinoma. The tumor measured 1.5 cm in the greatest dimension and stained positive for insulin, chromogranin, and synaptophysin. The Ki-67 (MIB-1) labeling index was 1% to 2% and the mitotic count was 1/10 high-power fields. One patient had negative anatomic imaging studies (CT, MRI, and ultrasound), and no lesion was identified using IO ultrasound. The patient underwent an extended distal pancreatectomy and was biochemically cured. Pathology evaluation demonstrated multiple welldifferentiated neuroendocrine tumors, the largest measuring 4 mm. The neuroendocrine tumors present stained positively for chromogranin and insulin and negative for gastrin, glucagon, pancreatic polypeptide, and somatostatin.
Accuracy of imaging modalities in entire study cohort
Out of the 31 patients with pathology-confirmed insulinoma, CT accurately localized the lesion in 17 out of 31 patients (55%, average tumor size of 1.37 cm).
MRI localized the insulinoma in 17 out of 28 patients (61%, average tumor size of 1.37 cm). In 12 patients, both CT and MRI were positive. Abdominal ultrasound accurately localized the insulinoma in 6 out of 28 (21%) of the patients. IO ultrasound was performed in 31 patients, in 29 of whom insulinoma was successfully localized (93%). In 23 patients who had an open or handassisted laparoscopic exploration, manual palpation identified 19 out of 23 (83%) of the insulinoma. In patients who had all 4 noninvasive imaging studies (CT, MRI, ultrasound, and 68 Ga-DOTATATE), CT was concordant with 68 Ga-DOTATATE in 6 out of 9 patients (67%) and MRI in 7 out of 9 (78%), and in 1 out of 9 patients (11%), the lesion was only seen by 68 Ga-DOTATATE (Table 2) . Transabdominal ultrasound was performed in 8 patients and did not localize the tumor in any of them.
Discussion
In this study, we compared the results of 68 Ga-DOTATATE PET/CT to other preoperative anatomic imaging and SASI to determine the accuracy of 68 Ga-DOTATATE. It was positive in 9 out of 10 patients. In 1 of the 10 patients in whom insulinoma was regionalized Mann-Whitney U test was used for the fasting end C-peptide, as these values were not normally distributed.
doi: 10.1210/jc.2016-3445 press.endocrine.org/journal/jcemwith SASI, 68 Ga-DOTATATE PET/CT was the only positive imaging study, as the other 5 imaging studies were negative. When we compared clinical variables, biochemical variables, treatment, patient outcome, and tumor histology, there was no significant difference between patients who underwent 68 Ga-DOTATATE PET/CT imaging vs those patients who did not have this imaging.
Insulinomas are associated with substantial morbidity and mortality when not treated. The only curative treatment of this tumor is surgical resection. However, localization of insulinoma can be challenging, as most tumors are often less than 2 cm and may be present in any part of the pancreas. Multiple preoperative imaging modalities may be used to localize insulinoma in addition to endoscopic ultrasound, but in most studies, SASI is the most accurate test for regionalizing the tumor. Whereas it is neither necessary nor cost effective to perform multiple imaging studies in patients with insulinoma, this was done at our institution under a clinical investigation protocol and allowed for a head-to-head comparison to evaluate the clinical utility, if any, of 68 Ga-DOTATATE scanning. 68 Ga-DOTATATE has a high affinity to somatostatin receptors 2, which are commonly expressed in neuroendocrine tumors (15) . Prasad et al. (12) found that somatostatin receptors 2 expression in insulinomas is present in up to 80% of cases.
68 Ga-DOTATATE PET/ CT has been reported to detect neuroendocrine tumors as small as 6 mm in size (11 Ga-DOTANOC, which successfully localized the insulinoma in 6 patients. Six patients underwent 68 Ga-DOTATATE, and an insulinoma was localized in 5 of them. Of these 5 patients, 1 had a benign insulinoma, 2 had malignant insulinomas, and 2 had nesidioblastosis (12) . 68 Ga-DOTA-exendin-4 PET/CT has also been evaluated in patients with insulinoma. Wild et al. detected 68 Ga-DOTANOC PET/CT imaging in 35 patients suspected to have insulinoma and reported a sensitivity of 25.8% and a specificity of 25%.
As the incidence of insulinoma is 0.1 to 0.3 cases per 100,000 persons per year (1), 1 of the limitations of our study is the low number of patients. In addition, not all of the patients had all of the imaging modalities performed, and only 10 patients underwent 68 Ga-DOTATATE PET/CT.
In summary,
68
Ga-DOTATATE PET/CT is a noninvasive imaging modality that identifies most insulinomas. It appears to offer limited additional information when other anatomic imaging studies localize the tumor and should be considered an adjunct when all imaging studies are negative in a patient with an insulinoma, especially if a focused or minimally invasive surgical approach is preferred.
